➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Mallinckrodt
McKesson
Johnson and Johnson
Merck

Last Updated: June 2, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for TAK-659


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for TAK-659?

TAK-659 is an investigational drug.

There have been 326 clinical trials for TAK-659. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2016.

The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).

There are three US patents protecting this investigational drug and fifty-three international patents.

Recent Clinical Trials for TAK-659
TitleSponsorPhase
Effect of TAK-071 on Falls in Patients With Parkinson DiseaseTakedaPhase 2
A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)TakedaPhase 1
A Safety and Efficacy Study of TAK-981 Plus Pembrolizumab in Participants With Select Advanced or Metastatic Solid TumorsTakeda Development Center Americas, Inc.Phase 1/Phase 2

See all TAK-659 clinical trials

Clinical Trial Summary for TAK-659

Top disease conditions for TAK-659
Top clinical trial sponsors for TAK-659

See all TAK-659 clinical trials

US Patents for TAK-659

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TAK-659   Start Trial Fused heteroaromatic pyrrolidinones Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
TAK-659   Start Trial Fused heteroaromatic pyrrolidinones Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
TAK-659   Start Trial Fused heteroaromatic pyrrolidinones as SYK inhibitors Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for TAK-659

Drugname Country Document Number Estimated Expiration Related US Patent
TAK-659 Argentina 081797 2029-12-23   Start Trial
TAK-659 Australia 2010333804 2029-12-23   Start Trial
TAK-659 Brazil 112012015651 2029-12-23   Start Trial
TAK-659 Canada 2786950 2029-12-23   Start Trial
TAK-659 Chile 2012001745 2029-12-23   Start Trial
TAK-659 China 102753548 2029-12-23   Start Trial
TAK-659 Colombia 6592058 2029-12-23   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Express Scripts
Medtronic
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.